Menu
Please read the submission guidelines carefully before submitting your abstract. All authors are required to adhere to these guidelines to ensure their submission is considered.
1. Abstracts may only be submitted online via Oxford Abstracts by May 22, 2026. Submissions via mail, e-mail, or fax will not be accepted.
2. Abstracts that do not conform to these guidelines will not be considered for review.
3. Abstracts must be submitted and presented in English.
4. The abstract title should clearly reflect the nature of the study or investigation.
5. Abstracts must be original and should not have been published elsewhere. Industry
presenters are welcome to submit, provided that they fully disclose any conflicts of interest.
6. Abbreviations should be avoided in titles but may be used in the text if defined at first usage.
7. Abstract structure:
8. Abstract Categories:
Precision Medicine in Hereditary Cancer
Biomarker-driven treatment, molecular stratification (e.g. dMMR/pMMR), personalised therapy
Prevention and Risk Reduction Strategies
Chemoprevention (e.g. aspirin), prophylactic surgery, lifestyle interventions
Immunotherapy and Vaccine Strategies
Immune checkpoint inhibitors, cancer vaccines, tumour–immune interactions
Surgical and Organ-Sparing Approaches
Minimally invasive surgery, organ preservation, non-operative management
Screening, Surveillance, and Early Detection
Screening strategies, non-invasive diagnostics, surveillance optimisation
Genetics, Counselling, and Patient Communication
Genetic counselling models, risk communication, ethical/psychosocial aspects
Registries, Biobanks, and Real-World Data
Registry-based research, biobank studies, penetrance and natural history
Clinical Trials, Study Design, and Collaboration
Study proposals, feasibility work, international collaborations, trial innovation
Rare Tumours and Expanded Phenotypes
Rare hereditary cancers, non-classical Lynch-associated tumours, phenotype expansion
Health Policy, Guidelines, and Implementation Science
Guideline development, health systems, implementation into practice
9. The abstract length (including introduction, methods, results, and conclusion) must not
exceed 250 words, excluding the title, author names, affiliations, references, and disclosures.
10. A maximum of one table or image may be included in the abstract.
11. The use of trademarks is prohibited. Only International Non-Proprietary Names (INN), such as generic drug names, are allowed.
12. Indicate a minimum of two and a maximum of three keywords that best describe your abstract’s content.
13. As the EHTG is committed to providing high-quality educational sessions free from commercial influence or bias, all potential conflicts of interest must be declared.
14. The submitting author must declare any potential conflicts of interest for all authors during submission. The following details must also be provided:
15. Avoid vague statements such as "data will be presented" instead, include the actual data
within the abstract.
16. Abstracts can be saved as drafts and completed later. However, drafts must be submitted before the deadline to be considered. Draft abstracts will not be reviewed.
17. Upon submission, the system will generate a temporary abstract number, which must be used in all correspondence. If you do not receive this number immediately, your abstract has not been registered. In this case, please contact the secretariat.
18. Submission of an abstract constitutes a formal commitment by the author to present it in the assigned session as determined by the EHTG Program Committee.
19. Abstracts will be peer-reviewed by a panel of experts. Notification of acceptance or rejection will be sent via email to the submitter and presenting author at the address provided during submission.
We look forward to receiving your submissions!
